Abstract Details

Title Adipose-derived Mesenchymal Stem Cells Ameliorate Neuroinflammation and promote neurogenesis in a Transgenic Mouse Model of Huntington’s disease

Topic Movement Disorders

Presentation(s) S11 - Huntington's Disease, Tardive Dyskinesia, and Functional Movement Disorders (4:54 PM-5:06 PM)

Poster/Presentation
Number 008

Objective To investigate the efficacy of adipose derived mesenchymal stem cells on neuroinflammation and neurogenesis in a transgenic Huntington's disease mouse model.

Background

Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric disturbances associated with neuronal dysfunction and atrophy of the striatum and other brain regions. To date, there are no effective disease modifying treatments approved for HD. Because restorative therapies targeting the underlying cause of neuronal dysfunction do not exist, therapies with anti-inflammatory, neuroprotective and regenerative potential hold great promise. Neuroinflammation is an early pathological feature of HD. Previous studies reported Iba1 and GFAP immunoreactivities in the brains of presymptomatic carriers and an increase with disease progression. Mesenchymal stem cells (MSCs) have demonstrated significant therapeutic effects in various neuroinflammatory diseases.

Design/Methods In this study, we examined the therapeutic effect of a commercial preparation of adipose-derived MSCs (HB-AdMSCs) on neuroinflammation and neurogenesis in a transgenic HD mouse model. The cells were obtained from Hope Biosciences (Sugar Land, TX) and intravenously infused twice, first at 7 weeks of age and then at 10 weeks of age of B6CBA-R6/2 transgenic HD or wildtype mice. No was given to any animal. The animals were perfused 14 days after the second cell injection to harvest the brains and perform immunohistochemical assays.

Results We observed that HB-AdMSCs were able to significantly reduce astrocyte reactivity in the cortical region of the HD brains compared to controls. The cells also significantly reduced microglial reactivity and induced neurogenesis in the striatum.

Conclusions We conclude that administration of HB-AdMSCs could ameliorate the inflammatory microenvironment in the brain to support survival of damaged neurons and improve neurogenesis as demonstrated in a Huntington's disease transgenic mouse model.

Authors/Disclosures
Erin Furr-Stimming, MD, FAAN (University of Texas Health Science Center-Houston) PRESENTER	Dr. Furr-Stimming has received personal compensation for serving as an employee of Help4HD International. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedPage. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Latus Bio. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atalanta Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SkyHawk Therapeutics. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine Bioscienes. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from Sage Therapeutics. The institution of Dr. Furr-Stimming has received research support from HDSA. The institution of Dr. Furr-Stimming has received research support from Prilennia. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has a non-compensated relationship as a Committee member with AAN UES Committee that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Gabriela Colpo	Gabriela Colpo has nothing to disclose.
	No disclosure on file
Andrey Tsvetkov	No disclosure on file
Scott D. Olson, PhD (UT Health)	Dr. Olson has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Bryan Cave Leighton Paisner LLP. Dr. Olson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Smith Gambrell Russell via Teklicon. The institution of Dr. Olson has received research support from HART. The institution of Dr. Olson has received research support from Cellvation. The institution of Dr. Olson has received research support from Hope Bio. Dr. Olson has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��